✦ LIBER ✦

From monoamines to genomic targets: a paradigm shift for drug discovery in depression

✍ Scribed by Wong, Ma-Li; Licinio, Julio

Book ID: 109949419
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 557 KB
Volume: 3
Category: Article
ISSN: 1474-1776
DOI: 10.1038/nrd1303

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

It is time for a paradigm shift in drug

It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS

✍ Ragu Ramanathan; Mohammed Jemal; Suma Ramagiri; Yuan-Qing Xia; W. Griffith Humpr 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

## Abstract It can be argued that the last true paradigm shift in the bioanalytical (BA) arena was the shift from high‐performance liquid chromatography (HPLC) with ultraviolet (UV) detection to HPLC with tandem mass spectrometry (MS/MS) detection after the commercialization of the triple quadrupol

In Silico Drug Discovery: Solving the “T

In Silico Drug Discovery: Solving the “Target-rich and Lead-poor” Imbalance Using the Genome-to-drug-lead Paradigm

✍ Pang, Y P 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 217 KB

Lipases and Phospholipases in Drug Devel

Lipases and Phospholipases in Drug Development (From Biochemistry to Molecular Pharmacology) || Endothelial Lipase: A Novel Drug Target for HDL and Atherosclerosis?

✍ MÃ¼ller, GÃ¼nter; Petry, Stefan 📂 Article 📅 2005 🏛 Wiley-VCH Verlag GmbH & Co. KGaA 🌐 German ⚖ 292 KB 👁 1 views

Lipases And Phospholipases Are Key Control Elements In Mammalian Metabolism. They Share Many Common Features That Set Them Apart From Other Metabolic Enzyme Classes, Most Importantly Their Association With Biological Membranes. Their Potential As Drug Targets For The Treatment Of Metabolic Diseases